gabapentin has been researched along with Pernicious Vomiting of Pregnancy in 3 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Excerpt | Relevance | Reference |
---|---|---|
"This study aimed to determine whether gabapentin is more effective than standard-of-care therapy for treating hyperemesis gravidarum." | 9.41 | Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial. ( Guttuso, T; Messing, S; Mullin, P; Saha, S; Shepherd, R; Strittmatter, C; Thornburg, LL; Tu, X, 2021) |
" Gabapentin is currently FDA-approved for treating RLS and preliminary results have shown it may be effective for treating the most severe form of NVP, hyperemesis gravidarum (HG)." | 8.90 | Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014) |
"Among 7 subjects with hyperemesis gravidarum (HG), we found gabapentin therapy to be associated with mean reductions in nausea and emesis from Baseline to Days 12-14 of 80% and 94%, respectively." | 7.76 | Gabapentin use in hyperemesis gravidarum: a pilot study. ( Amankwah, KS; Guttuso, T; Robinson, LK, 2010) |
"This study aimed to determine whether gabapentin is more effective than standard-of-care therapy for treating hyperemesis gravidarum." | 5.41 | Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial. ( Guttuso, T; Messing, S; Mullin, P; Saha, S; Shepherd, R; Strittmatter, C; Thornburg, LL; Tu, X, 2021) |
" Gabapentin is currently FDA-approved for treating RLS and preliminary results have shown it may be effective for treating the most severe form of NVP, hyperemesis gravidarum (HG)." | 4.90 | Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. ( Guttuso, T; Shaman, M; Thornburg, LL, 2014) |
"Among 7 subjects with hyperemesis gravidarum (HG), we found gabapentin therapy to be associated with mean reductions in nausea and emesis from Baseline to Days 12-14 of 80% and 94%, respectively." | 3.76 | Gabapentin use in hyperemesis gravidarum: a pilot study. ( Amankwah, KS; Guttuso, T; Robinson, LK, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Guttuso, T | 3 |
Messing, S | 1 |
Tu, X | 1 |
Mullin, P | 1 |
Shepherd, R | 1 |
Strittmatter, C | 1 |
Saha, S | 1 |
Thornburg, LL | 2 |
Shaman, M | 1 |
Robinson, LK | 1 |
Amankwah, KS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum[NCT02163434] | Phase 2 | 31 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
"Determining the Effect of an Alternate Recovery Protocol Versus Current Standard of Care After Cesarean Section"[NCT03330119] | Phase 3 | 1,494 participants (Actual) | Interventional | 2017-10-04 | Terminated (stopped due to Lack of Funding/ Resident in charge graduated) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Score range: 6-30 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week
Intervention | units on a scale (Mean) |
---|---|
Gabapentin | 6.35 |
Metoclopramide | 13.22 |
Score range: 2-10 with higher score indicating a worse outcome. (NCT02163434)
Timeframe: 1 week
Intervention | units on a scale (Mean) |
---|---|
Gabapentin | 2.01 |
Metoclopramide | 3.69 |
Score range: 0-15 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week
Intervention | units on a scale (Mean) |
---|---|
Gabapentin | 7.86 |
Metoclopramide | 4.01 |
Scores: 0=no, 1=yes. Thus, a higher score indicates a better outcome. (NCT02163434)
Timeframe: 1 week
Intervention | units on a scale (Mean) |
---|---|
Gabapentin | 0.67 |
Metoclopramide | 0.14 |
Score range: 0-4 with higher score indicating a better outcome. (NCT02163434)
Timeframe: 1 week
Intervention | units on a scale (Mean) |
---|---|
Gabapentin | 2.22 |
Metoclopramide | 0.63 |
(NCT02163434)
Timeframe: 1 week
Intervention | Participants (Count of Participants) |
---|---|
Gabapentin | 5 |
Metoclopramide | 5 |
"total narcotic utilization measured with Morphine Milligram Equivalent (MME)~The conversion scale being used will be the Center for Disease Control and Prevention Morphine Equivalent Score.~Lower scores represent less opioid use and a better outcome. Higher scores represent more opioid use and a worse outcome." (NCT03330119)
Timeframe: From time of consent until hospital discharge (3 days)
Intervention | MME (Mean) |
---|---|
Alternate Management | 33.3 |
Control | 47.2 |
1 review available for gabapentin and Pernicious Vomiting of Pregnancy
Article | Year |
---|---|
Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy.
Topics: Amines; Anticonvulsants; Birth Weight; Congenital Abnormalities; Cyclohexanecarboxylic Acids; Female | 2014 |
1 trial available for gabapentin and Pernicious Vomiting of Pregnancy
Article | Year |
---|---|
Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial.
Topics: Antiemetics; Female; Gabapentin; Humans; Hyperemesis Gravidarum; Infant, Newborn; Ondansetron; Pregn | 2021 |
1 other study available for gabapentin and Pernicious Vomiting of Pregnancy
Article | Year |
---|---|
Gabapentin use in hyperemesis gravidarum: a pilot study.
Topics: Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hyp | 2010 |